Securities code: 300942 securities abbreviation: Shenzhen Bioeasy Biotechnology Co.Ltd(300942) Announcement No.: 2022-011 Shenzhen Bioeasy Biotechnology Co.Ltd(300942)
Announcement of resolutions of the 10th meeting of the second board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
Shenzhen Bioeasy Biotechnology Co.Ltd(300942) (hereinafter referred to as “the company”) held the 10th meeting of the second session of the board of supervisors in the company’s conference room on the 5th floor, No. 2-1 Liuxian 1st Road, Bao’an District, Shenzhen on February 25, 2022 (Friday). The notice of this meeting was sent to all supervisors by email and communication on February 21, 2022.
The meeting was convened and presided over by Mr. Wang Bingzhi, chairman of the board of supervisors. Three supervisors should attend the meeting and three actually attended the meeting; The Secretary of the board of directors and securities affairs representative of the company attended the meeting as nonvoting delegates. The convening, notification, convening and voting procedures of this meeting comply with the relevant provisions of the company law and other relevant laws, administrative regulations, normative documents, departmental rules and the articles of association. The meeting is legal and effective.
2、 Deliberation at the meeting of the board of supervisors
After deliberation by the supervisors attending the meeting and voting by open ballot in writing, the deliberation results are as follows:
(I) deliberated and passed the proposal on cooperative investment with professional investment institutions
Through cooperation with professional investment institutions, under the condition of ensuring the stable development of the company’s main business, this investment expands the company’s project investment channels with the help of the advantages and resources of the partnership, which is conducive to improving the company’s capital use efficiency and foreign investment ability. The capital source of the investment is the company’s own funds, which will not affect the normal operation of the company’s production and operation activities, and will not have a significant impact on the company’s financial and operating conditions. Therefore, all supervisors unanimously agreed to the proposal.
Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
The announcement on cooperative investment with professional investment institutions (Announcement No.: 2022-012) was published on the information disclosure website cninfo.com (www.cn. Info. Com. CN) on the same day.
The motion was passed.
(II) the proposal on the use of some temporarily idle raised funds for cash management was deliberated and adopted. The company is in good operation and stable financial condition. The company uses part of the temporarily idle raised funds with a total amount of no more than RMB 100 million for cash management, and there is no situation affecting the normal construction of the investment projects with raised funds and the safety of the raised funds. Reasonable use of idle raised funds for cash management can increase income and obtain better returns for the company and shareholders, which is in line with the interests of the company, does not harm the interests of the company and all shareholders, and complies with the relevant provisions of relevant laws, regulations and normative documents. Therefore, all supervisors unanimously agreed to the proposal.
Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
The announcement on the use of some temporarily idle raised funds for cash management (Announcement No.: 2022-013) was published on the information disclosure website cninfo.com (www.cn. Info. Com. CN) on the same day.
The motion was passed.
3、 Documents for future reference
1. Resolution of the 10th meeting of the second board of supervisors of the company.
It is hereby announced.
Shenzhen Bioeasy Biotechnology Co.Ltd(300942) board of supervisors February 26, 2022
